Skip to main content
Top

2024 | OriginalPaper | Hoofdstuk

41. Ovarian cancer

Auteurs : Prof. dr. Marian J. E. Mourits, Drs. Florine A. Eggink, Dr. Mathilde Jalving, Dr. Marco de Bruyn, Dr. Joost Bart, Prof. dr. Hans W. Nijman

Gepubliceerd in: Textbook of Obstetrics and Gynaecology

Uitgeverij: Bohn Stafleu van Loghum

share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail

Summary

Ovarian cancer is a relatively uncommon type of cancer, and the most common form of it (90 %) is epithelial. Other histotypes include non-epithelial and metastatic tumours. Epithelial ovarian cancers form a heterogeneous group with high-grade serous carcinoma (HGSC) being the most common subtype, which we now assume originates in the distal part of the fallopian tube. In the absence of specific early symptoms, most patients with ovarian cancer are diagnosed with advanced stage disease. Standard therapy for ovarian cancer comprises a combination of surgery and chemotherapy. In most European countries, surgical therapy for patients with ovarian cancer is centralised in specialised hospitals, which often provide chemotherapy in conjunction with neighbouring hospitals. This allows more cases to be handled and surgical expertise to be concentrated. Despite an initial response, most patients develop resistance to chemotherapy. The prognosis of patients with ovarian cancer is therefore unfavourable and ten-year survival has not improved recently. Innovative therapeutic strategies – such as ones based on genetic and molecular subtyping – are increasingly being developed to improve treatment outcome.
Bijlagen
Alleen toegankelijk voor geautoriseerde gebruikers
Woordenlijst
Adjuvant chemotherapy
Therapy that is given after the primary surgery to decrease the risk of recurrence.
Cytoreduction
Reducing the number of macroscopic tumour cells.
Cytotoxic
Any agent or process that kills cells.
Exfoliation
Process of spontaneous or induced complete detachment of single epithelial (tumour) cells.
Neo-adjuvant chemotherapy
Therapy that is given before the primary surgery to reduce tumour volume.
Neo-antigens
Newly exposed antigen.
Sex cord-stromal tumours (SCSTs)
Tumours composed of pure stromal cells, pure sex cord cells or a combination.
Literatuur
1.
go back to reference Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H, Mannel RS, Homesley HD, Fowler J, Greer BE, Boente M, Birrer MJ, Liang SX; Gynecologic Oncology Group. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011 Dec 29;365(26):2473–83. Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H, Mannel RS, Homesley HD, Fowler J, Greer BE, Boente M, Birrer MJ, Liang SX; Gynecologic Oncology Group. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011 Dec 29;365(26):2473–83.
2.
go back to reference Collinson F, Qian W, Fossati R, Lissoni A, Williams C, Parmar M, Ledermann J, Colombo N, Swart A; ICON1 collaborators. Optimal treatment of early-stage ovarian cancer. Ann Oncol. 2014;25(6):1165–71. Collinson F, Qian W, Fossati R, Lissoni A, Williams C, Parmar M, Ledermann J, Colombo N, Swart A; ICON1 collaborators. Optimal treatment of early-stage ovarian cancer. Ann Oncol. 2014;25(6):1165–71.
3.
go back to reference Harter P, Sehouli J, Vergote I, Ferron G, Reuss A, Meier W, Greggi S, Mosgaard BJ, Selle F, Guyon F, Pomel C, Lécuru F, Zang R, Avall-Lundqvist E, Kim JW, Ponce J, Raspagliesi F, Kristensen G, Classe JM, Hillemanns P, Jensen P, Hasenburg A, Ghaem-Maghami S, Mirza MR, Lund B, Reinthaller A, Santaballa A, Olaitan A, Hilpert F, Du Bois A; DESKTOP III Investigators. Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer. N Engl J Med. 2021 Dec 2;385(23):2123-2131. doi: https://doi.org/10.1056/NEJMoa2103294. Erratum in: N Engl J Med. 2022 Feb 17;386(7):704. PMID: 34874631. Harter P, Sehouli J, Vergote I, Ferron G, Reuss A, Meier W, Greggi S, Mosgaard BJ, Selle F, Guyon F, Pomel C, Lécuru F, Zang R, Avall-Lundqvist E, Kim JW, Ponce J, Raspagliesi F, Kristensen G, Classe JM, Hillemanns P, Jensen P, Hasenburg A, Ghaem-Maghami S, Mirza MR, Lund B, Reinthaller A, Santaballa A, Olaitan A, Hilpert F, Du Bois A; DESKTOP III Investigators. Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer. N Engl J Med. 2021 Dec 2;385(23):2123-2131. doi: https://​doi.​org/​10.​1056/​NEJMoa2103294. Erratum in: N Engl J Med. 2022 Feb 17;386(7):704. PMID: 34874631.
4.
go back to reference Menon U, Gentry-Maharaj A, Burnell M, Singh N, Ryan A, Karpinskyj C, Carlino G, Taylor J, Massingham SK, Raikou M, Kalsi JK, Woolas R, Manchanda R, Arora R, Casey L, Dawnay A, Dobbs S, Leeson S, Mould T, Seif MW, Sharma A, Williamson K, Liu Y, Fallowfield L, McGuire AJ, Campbell S, Skates SJ, Jacobs IJ, Parmar M. Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. Lancet. 2021;397(10290):2182–93. https://doi.org/10.1016/S0140-6736(21)00731-5. Epub 2021 May 12PMID: 33991479.CrossRefPubMedPubMedCentral Menon U, Gentry-Maharaj A, Burnell M, Singh N, Ryan A, Karpinskyj C, Carlino G, Taylor J, Massingham SK, Raikou M, Kalsi JK, Woolas R, Manchanda R, Arora R, Casey L, Dawnay A, Dobbs S, Leeson S, Mould T, Seif MW, Sharma A, Williamson K, Liu Y, Fallowfield L, McGuire AJ, Campbell S, Skates SJ, Jacobs IJ, Parmar M. Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. Lancet. 2021;397(10290):2182–93. https://​doi.​org/​10.​1016/​S0140-6736(21)00731-5. Epub 2021 May 12PMID: 33991479.CrossRefPubMedPubMedCentral
5.
go back to reference Oza AM, Cook AD, Pfisterer J, Embleton A, Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P, Cervantes A, Park-Simon TW, Rustin G, Joly F, Mirza MR, Plante M, Quinn M, Poveda A, Jayson GC, Stark D, Swart AM, Farrelly L, Kaplan R, Parmar MK, Perren TJ; ICON7 trial investigators. Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. Lancet Oncol. 2015;16(8):928–36. Oza AM, Cook AD, Pfisterer J, Embleton A, Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P, Cervantes A, Park-Simon TW, Rustin G, Joly F, Mirza MR, Plante M, Quinn M, Poveda A, Jayson GC, Stark D, Swart AM, Farrelly L, Kaplan R, Parmar MK, Perren TJ; ICON7 trial investigators. Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. Lancet Oncol. 2015;16(8):928–36.
6.
go back to reference Piek JM, Van Diest PJ, Zweemer RP, Jansen JW, Poort-Keesom RJ, Menko FH, Gille JJ, Jongsma AP, Pals G, Kenemans P, Verheijen RH. Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer. J Pathol. 2001;195(4):451–6.CrossRefPubMed Piek JM, Van Diest PJ, Zweemer RP, Jansen JW, Poort-Keesom RJ, Menko FH, Gille JJ, Jongsma AP, Pals G, Kenemans P, Verheijen RH. Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer. J Pathol. 2001;195(4):451–6.CrossRefPubMed
7.
8.
go back to reference Steenbeek MP, Van Bommel MHD, Bulten J, Hulsmann JA, Bogaerts J, Garcia C, Cun HT, Lu KH, Van Beekhuizen HJ, Minig L, Gaarenstroom KN, Nobbenhuis M, Krajc M, Rudaitis V, Norquist BM, Swisher EM, Mourits MJE, Massuger LFAG, Hoogerbrugge N, Hermens RPMG, IntHout J, De Hullu JA. Risk of Peritoneal Carcinomatosis After Risk-Reducing Salpingo-Oophorectomy: A Systematic Review and Individual Patient Data Meta-Analysis. J Clin Oncol. 2022;40(17):1879–91. https://doi.org/10.1200/JCO.21.02016. Epub 2022 Mar 18. PMID: 35302882; PMCID: PMC9851686. Steenbeek MP, Van Bommel MHD, Bulten J, Hulsmann JA, Bogaerts J, Garcia C, Cun HT, Lu KH, Van Beekhuizen HJ, Minig L, Gaarenstroom KN, Nobbenhuis M, Krajc M, Rudaitis V, Norquist BM, Swisher EM, Mourits MJE, Massuger LFAG, Hoogerbrugge N, Hermens RPMG, IntHout J, De Hullu JA. Risk of Peritoneal Carcinomatosis After Risk-Reducing Salpingo-Oophorectomy: A Systematic Review and Individual Patient Data Meta-Analysis. J Clin Oncol. 2022;40(17):1879–91. https://​doi.​org/​10.​1200/​JCO.​21.​02016. Epub 2022 Mar 18. PMID: 35302882; PMCID: PMC9851686.
9.
go back to reference Van Driel WJ, Koole SN, Sikorska K, Schagen van Leeuwen JH, Schreuder HWR, Hermans RHM, De Hingh IHJT, Van der Velden J, Arts HJ, Massuger LFAG, Aalbers AGJ, Verwaal VJ, Kieffer JM, Van de Vijver KK, Van Tinteren H, Aaronson NK, Sonke GS. Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer. N Engl J Med. 2018;378(3):230–40. https://doi.org/10.1056/NEJMoa1708618. PMID: 29342393. Van Driel WJ, Koole SN, Sikorska K, Schagen van Leeuwen JH, Schreuder HWR, Hermans RHM, De Hingh IHJT, Van der Velden J, Arts HJ, Massuger LFAG, Aalbers AGJ, Verwaal VJ, Kieffer JM, Van de Vijver KK, Van Tinteren H, Aaronson NK, Sonke GS. Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer. N Engl J Med. 2018;378(3):230–40. https://​doi.​org/​10.​1056/​NEJMoa1708618. PMID: 29342393.
10.
go back to reference Wright AA, Bohlke K, Armstrong DK, Bookman MA, Cliby WA, Coleman RL, Dizon DS, Kash JJ, Meyer LA, Moore KN, Olawaiye AB, Oldham J, Salani R, Sparacio D, Tew WP, Vergote I, Edelson MI. Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: society of gynecologic oncology and American society of clinical oncology clinical practice guideline. J Clin Oncol. 2016;34(28):3460–73.CrossRefPubMed Wright AA, Bohlke K, Armstrong DK, Bookman MA, Cliby WA, Coleman RL, Dizon DS, Kash JJ, Meyer LA, Moore KN, Olawaiye AB, Oldham J, Salani R, Sparacio D, Tew WP, Vergote I, Edelson MI. Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: society of gynecologic oncology and American society of clinical oncology clinical practice guideline. J Clin Oncol. 2016;34(28):3460–73.CrossRefPubMed
Metagegevens
Titel
Ovarian cancer
Auteurs
Prof. dr. Marian J. E. Mourits
Drs. Florine A. Eggink
Dr. Mathilde Jalving
Dr. Marco de Bruyn
Dr. Joost Bart
Prof. dr. Hans W. Nijman
Copyright
2024
Uitgeverij
Bohn Stafleu van Loghum
DOI
https://doi.org/10.1007/978-90-368-2994-6_41